Cargando…
Cytokine Release Syndrome: Current Perspectives
Chimeric antigen receptor T cell (CART) therapy represents a novel and a paradigm-shifting approach to treating cancer. Recent clinical successes have widened the applicability of CD19 CART cells for the treatment of relapsed/refractory B-cell NHL, namely tisagenleclucel and axicabtagene ciloleucel....
Autores principales: | Murthy, Hemant, Iqbal, Madiha, Chavez, Julio C, Kharfan-Dabaja, Mohamed A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825470/ https://www.ncbi.nlm.nih.gov/pubmed/31754614 http://dx.doi.org/10.2147/ITT.S202015 |
Ejemplares similares
-
Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes
por: Mohty, Razan, et al.
Publicado: (2023) -
Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions
por: Chavez, Julio C, et al.
Publicado: (2021) -
CAR T-cell therapy for B-cell lymphomas: clinical trial results of
available products
por: Chavez, Julio C., et al.
Publicado: (2019) -
Recent advances in immunotherapy for B-cell non-Hodgkin lymphoma and multiple myeloma
por: Chavez, Julio C., et al.
Publicado: (2022) -
Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience
por: Yassine, Farah, et al.
Publicado: (2023)